varisacumab (AT001 (r84)) / Affitech, Feng Biosciences, Generium - LARVOL DELTA

Oncologie closes an $80M series B financing for clinical-stage pipeline (PRNewswire) - "The funding will be used to advance Oncologie's three clinical stage programs, as well as its proprietary biomarker platform and in-licensing activities. Oncologie will initiate key clinical trials in the coming months, including a global proof of concept gastric cancer study with its lead compound, bavituximab, in combination with pembrolizumab (Keytruda)...Oncologie's other programs include a TLR9 activator, lefitolimod, and a unique VEGF-targeting antibody, varisacumab."

Financing • New trial